PT  - JOURNAL ARTICLE
AU  - Buckley, Rita
TI  - Downregulation of ERCC1 Boosts Efficacy of Platinum-Based NSCLC Chemotherapy
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 8--8
VI  - 14
IP  - 3
4099  - http://mdc.sagepub.com/content/14/3/8.short
4100  - http://mdc.sagepub.com/content/14/3/8.full
AB  - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may reduce excision repair cross-complementing group 1 (ERCC1) gene expression, potentially enhancing sensitivity to platinum-based chemotherapy in patients with non—small cell lung cancer (NSCLC), according to results from a poster presented by Cheong et al. [Cheong HT et al. J Thorac Oncol 2014].